|
|
Post by agedhippie on Sept 30, 2023 11:39:32 GMT -5
Mike's problem is the speed of evolution of pumps, he is stuck in the old days of dumb pumps because unless you keep current on the paper that where that's where the mainstream data is. It's the same with the idea that HbA1c results haven't changed much - that true if you ignore the current generation of pumps, but definitely not true if you look at pumps like the Tandem Control:IQ, Omnipod 5, or Medtronics 780G as these will all get you below that target. The current generation can hit 75%+ TIR with minimal effort and 80%+ is pretty commonplace. People aren't jumping from pump to pump for fun, it's because at this point in time each generation is noticeably better than the last so why wouldn't you change? The idea that RAA is to slow for meals is flatly wrong if you are using one of these systems (see the TIR results). The problem is that to get those results you have to be continually taking and adjusting insulin on a minute to minute basis. This is not possible for humans, but trivial for computers and pumps like AID systems. The problem with diabetes today is that people are hung up on old data in a world that is rapidly evolving. When Mike says things like HbA1c has not improved for decades it just makes him look out of touch because the people he needs to reach, who are the thought leaders, know that is no longer the case. This is double edged sword for Afrezza because the slower moving doctors will stick to what they know and the SoC (Mike's comment about the need for education), and the leaders are already onto AID and Afrezza as a rescue inhaler. |
|
|
|
Post by sayhey24 on Sept 30, 2023 12:30:18 GMT -5
Purchasing VGo seems to have been MC's idea. If MC tries to push Afrezza for T2D it would be equivalent to admitting he was wrong about VGo and no CEO would ever admit they made a bad decision. V-Go was clearly Mike's idea but things have changed. At the time he was sending out the sales reps and they had nothing for the T2 market. V-Go allowed Mike to put something in the reps "bags" which could start the conversation and even make a few sales. When Mike bought V-Go afrezza has been put on the shelf for 4+ years for the T2 market because Mike had not done the spade work and did not know how to sell it into the T2 market. Granted he also did not have the money to do the required follow-on studies. He was also still learning that if you followed the label you were under dosing and not getting the results which you could. Mike now understands the dosing issue. We now have $35 Medicare coverage (with pre auths) and we have near free Medicare CGMs with any insulin. We also have the India results coming soon and if they properly dosed we should see the 1.5 - 2.0 A1c reduction Mike mentioned a few calls back. The reality is V-Go is something the reps have in their "bags". At the time it was bought Mike can argue it was not a mistake. Its never going to make much money for MNKD and at some point once Mike develops his T2 strategy for afrezza V-Go won't fit into the strategy. At that point you can close it down or sell it. Maybe the V-Go management/sales reps can raise some money and buy it. That should be some time in 2025 unless they can't "stabilize it" by year end. |
|
|
|
Post by agedhippie on Sept 30, 2023 15:12:49 GMT -5
... Mike now understands the dosing issue. We now have $35 Medicare coverage (with pre auths) and we have near free Medicare CGMs with any insulin. We also have the India results coming soon and if they properly dosed we should see the 1.5 - 2.0 A1c reduction Mike mentioned a few calls back. ... The Medicare coverage is already there and Mike was crystal clear on this at the Morgan Stanley conference, he sees V-Go is for Type 2, Afrezza is for Type 1. What to you expect the India results to do? They are repeating the the 175 trial so the comparison is insulin vs. nothing. I would certainly hope Afrezza could get a 1.5 - 2.0 reduction because GLP-1 analogs, which are the competitor for that step, all managed to get over 2.0 reduction last I looked. India may actually be a negative since the original aim was to increase the utilization of the Danbury plant to reduce overall production costs. Now that production capacity is needed for Tyvaso so meeting both schedules could be an issue (who do you want to upset?) |
|
|
|
Post by sportsrancho on Oct 1, 2023 11:21:17 GMT -5
OK wait …Mike’s not selling Afrezza to the type2 market anymore. You mean the reps go in there and they say Afrezza is for type1 and here’s the patch for type2?
|
|
|
|
Post by agedhippie on Oct 1, 2023 12:49:34 GMT -5
OK wait …Mike’s not selling Afrezza to the type2 market anymore. You mean the reps go in there and they say Afrezza is for type1 and here’s the patch for type2? Allowing for the transcript... This is from the Morgan Stanley conference: " But V-Go itself has been a great device. We've positioned that for type 2, so I talked about Afrezza for type 1." " So when our sales force is out there, if they're not going to write in a inhaled insulin, then you've got plenty of patients that have type 2. Let's try to help those patients. And that's really our focus, is making sure our sales force is efficient and effective, and bringing as many offerings to customers as we can." My read of that is the salesforce will push for Afrezza Type 1 market if there is resistance, but in the Type 2 if there is an resistance switch the conversation to V-Go. |
|
|
|
Post by mytakeonit on Oct 2, 2023 2:39:20 GMT -5
Key words ... "if there is a resistance in the Type 2 market"
Buy more cheap shares !!!
But, that's mytakeonit
|
|
|
|
Post by sayhey24 on Oct 2, 2023 8:40:46 GMT -5
OK wait …Mike’s not selling Afrezza to the type2 market anymore. You mean the reps go in there and they say Afrezza is for type1 and here’s the patch for type2? Allowing for the transcript... This is from the Morgan Stanley conference: " But V-Go itself has been a great device. We've positioned that for type 2, so I talked about Afrezza for type 1." " So when our sales force is out there, if they're not going to write in a inhaled insulin, then you've got plenty of patients that have type 2. Let's try to help those patients. And that's really our focus, is making sure our sales force is efficient and effective, and bringing as many offerings to customers as we can." My read of that is the salesforce will push for Afrezza Type 1 market if there is resistance, but in the Type 2 if there is an resistance switch the conversation to V-Go. Aged - yes, Mike has said this numerous times. Afrezza for the T2 market was put on the shelf 5+ years ago. He tried the "Seeing is Believing" campaign and it was an epic fail after spending $6M on it. I am sure he is a bit gun shy at this time and wants to wait on the trial results. At this point in time Mike has put V-Go in the sales reps "bags" for the T2 market. The key phrase is "at this point in time". Sometimes things change. We expect the India results will be outstanding. If so let see what MNKD decides to do. Mike has said several times GLP1s just delay the use of insulin so he has been thinking about GLP1s and who knows maybe after the India results he will announce the glp1/afrezza study he mentioned earlier in the year. Afrezza and GLP1s don't have to be an either/or. Adding afrezza day1 to the GLP1 may be a winner. I think we can all agree V-Go is never going to make MNKD rich. He has however provided something for the sales reps to sell even if its a stop gap measure. Coming up to bat in 2024 we have some things to focus on in the T1 market which look like sure things. Assuming the kids results are great the moms will drive T1 sales going into 2025 and provide enough ammunition to start T1 SoC discussions. I would be more aggressive in the T2 market and would have already started the glp1/afrezza trial but Mike wants to wait on existing trial results and move slow and steady with other things in the pipeline. He has gotten burned so many times with afrezza I am sure he does not want another floating hamburger. For V-Go he is still using the word "stabilizing" when talking about it. I think this will bleed in 2024 and this time next year he will need to make some decisions. If the V-Go management really believes in the product they may want to think about how they could buy it from MNKD in a couple of years. |
|
|
|
Post by Clement on Dec 28, 2023 6:55:37 GMT -5
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, California.
|
|
|
|
Post by mymann on Jan 3, 2024 18:45:00 GMT -5
Don't let Mike present at the JPM conference. Mnkd sp probably going go below 3's. God help us.
|
|
|
|
Post by cretin11 on Jan 3, 2024 21:26:57 GMT -5
Don't let Mike present at the JPM conference. Mnkd sp probably going go below 3's. God help us. He does seem to have an uncanny knack for that, but hopefully his powers are not quite that strong. |
|
|
|
Post by mymann on Jan 11, 2024 18:46:38 GMT -5
As I predicted, Mike talks sp tanks.
|
|
|
|
Post by gamblerjag on Jan 11, 2024 19:08:11 GMT -5
As I predicted, Mike talks sp tanks. Man, you’re always so negative didn’t you say back in November that you weren’t a post anymore… yes you did on November 2… I remember cause I went out and celebrated |
|
|
|
Post by mymann on Jan 11, 2024 19:11:14 GMT -5
Just like Mike, I lied.
|
|
|
|
Post by gamblerjag on Jan 11, 2024 19:11:49 GMT -5
. Mike is helping with the future I’m not seeing your post doing that. |
|
|
|
Post by celo on Jan 12, 2024 1:10:54 GMT -5
I don't get it. Just listened to the JPMorgan call.
Mannkind has 300 million in the bank. Sold 1% of royalty for 200 million. So that segment of their total line of revenue streams is valued at 2 billion.
They still will receive collaboration and services revenue 50 million/year
They still have their other products sales revenue 2024 100 million/year
2 products that have big markets withe little or no true competition. Mnkd - 101 and Mnkd - 201.
Market cap is 934 million. Price to sales ratio of less than 5.
claimed to be severely undervalued. Why is it so undervalued?
Everyone saying it is a buy, but no one seems to be.
I don't need anyone to answer this post. Just befuddled. I know the story of this stock way to well.
I feel so lucky to be a part of this super enigma....umm no.
|
|
